CIM
XBI icon

Contravisory Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Contravisory Investment Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-33
Closed -$2K – 342
2016
Q4 		$2K Buy
+33
New +$2.04K ﹤0.01% 265

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

Contravisory Investment Management's XBI Position: Q1 2017 in Review

Contravisory Investment Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 33 shares — an estimated $2K sold.

Contravisory Investment Management first reported a position in XBI in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

  • Contravisory Investment Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
  • Contravisory Investment Management sold 33 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $2K.
  • Contravisory Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 1 quarter.
  • Contravisory Investment Management's State Street SPDR S&P Biotech ETF position peaked at $2K in Q4 2016.
  • 292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Contravisory Investment Management's 13F filing for Q1 2017, filed 7 Apr 2017.